IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review
Authors
Keywords
-
Journal
Modern Rheumatology
Volume -, Issue -, Pages 1-10
Publisher
Informa UK Limited
Online
2018-11-15
DOI
10.1080/14397595.2018.1546357
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tocilizumab discontinuation after attaining remission in patients with rheumatoid arthritis who were treated with tocilizumab alone or in combination with methotrexate: results from a prospective randomised controlled study (the second year of the SURPRISE study)
- (2018) Yuko Kaneko et al. ANNALS OF THE RHEUMATIC DISEASES
- Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting
- (2018) Tatsuya Atsumi et al. Modern Rheumatology
- Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
- (2018) Andrew I Rutherford et al. RHEUMATOLOGY
- Safety of Tocilizumab in Rheumatoid Arthritis Patients with Resolved Hepatitis B Virus Infection: Data from Real-World Experience
- (2018) Sung Soo Ahn et al. YONSEI MEDICAL JOURNAL
- Interleukin (IL)-6 Inhibits IL-27- and IL-30-Mediated Inflammatory Responses in Human Monocytes
- (2018) Carlene Petes et al. Frontiers in Immunology
- Tocilizumab and the risk for cardiovascular disease: a direct comparison among biologic disease-modifying antirheumatic drugs for rheumatoid arthritis patients
- (2018) Fenglong Xie et al. ARTHRITIS CARE & RESEARCH
- Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation
- (2017) Le-Feng Chen et al. International Journal of Rheumatic Diseases
- Epstein-Barr virus-induced gene 3 (EBI3) can mediate IL-6trans-signaling
- (2017) Salma Chehboun et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis
- (2017) Alan Kivitz et al. JOURNAL OF RHEUMATOLOGY
- Prodromal signs and symptoms of serious infections with tocilizumab treatment for rheumatoid arthritis: Text mining of the Japanese postmarketing adverse event-reporting database
- (2017) Tatsuya Atsumi et al. Modern Rheumatology
- A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period
- (2017) Atsushi Ogata et al. Modern Rheumatology
- Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries
- (2017) Ernest Choy et al. RHEUMATOLOGY
- THE CHALLENGES OF RARE RHEUMATIC DISEASESI79. CHALLENGES OF DIAGNOSING AND MANAGING PATIENTS WITH RARE DISEASES
- (2017) Robert Moots RHEUMATOLOGY
- 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty
- (2017) Susan M. Goodman et al. ARTHRITIS CARE & RESEARCH
- Treatment of Rheumatoid Arthritis With Anti-Tumor Necrosis Factor or Tocilizumab Therapy as First Biologic Agent in a Global Comparative Observational Study
- (2017) Ernest H. Choy et al. ARTHRITIS CARE & RESEARCH
- Profile of sarilumab and its potential in the treatment of rheumatoid arthritis
- (2017) Maria Gabriella Raimondo et al. Drug Design Development and Therapy
- Transaminase Levels and Hepatic Events During Tocilizumab Treatment: Pooled Analysis of Long-Term Clinical Trial Safety Data in Rheumatoid Arthritis
- (2017) Mark C. Genovese et al. Arthritis & Rheumatology
- Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs
- (2016) A Strangfeld et al. ANNALS OF THE RHEUMATIC DISEASES
- Comparison of adding tocilizumab to methotrexate with switching to tocilizumab in patients with rheumatoid arthritis with inadequate response to methotrexate: 52-week results from a prospective, randomised, controlled study (SURPRISE study)
- (2016) Yuko Kaneko et al. ANNALS OF THE RHEUMATIC DISEASES
- Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis
- (2016) Lotta Ljung et al. ANNALS OF THE RHEUMATIC DISEASES
- Low immunogenicity of tocilizumab in patients with rheumatoid arthritis
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Toxicities of chimeric antigen receptor T cells: recognition and management
- (2016) Jennifer N. Brudno et al. BLOOD
- Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis
- (2016) Rayford R. June et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
- (2016) Johannes W J Bijlsma et al. LANCET
- Pregnancy outcomes after exposure to tocilizumab: A retrospective analysis of 61 patients in Japan
- (2016) Ken Nakajima et al. Modern Rheumatology
- Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data
- (2016) Maria Hoeltzenbein et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
- (2016) Fenglong Xie et al. Arthritis & Rheumatology
- Interleukin-6 mediates exercise preconditioning against myocardial ischemia reperfusion injury
- (2015) Graham Ripley McGinnis et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
- (2015) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial
- (2015) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- The varying faces of IL-6: From cardiac protection to cardiac failure
- (2015) Jillian A. Fontes et al. CYTOKINE
- Longterm Safety and Efficacy of Subcutaneous Tocilizumab Monotherapy: Results from the 2-year Open-label Extension of the MUSASHI Study
- (2015) A. Ogata et al. JOURNAL OF RHEUMATOLOGY
- Sustainable Efficacy of Switching From Intravenous to Subcutaneous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2015) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy
- (2015) Huifeng Yun et al. ARTHRITIS CARE & RESEARCH
- Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
- (2014) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study
- (2014) T W J Huizinga et al. ANNALS OF THE RHEUMATIC DISEASES
- Biologic Therapies in Rheumatoid Arthritis and the Risk of Opportunistic Infections: A Meta-analysis
- (2014) Irene S. Kourbeti et al. CLINICAL INFECTIOUS DISEASES
- Interleukin-6, but not the interleukin-6 receptor plays a role in recovery from dextran sodium sulfate-induced colitis
- (2014) JAN SOMMER et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Transcriptional Complex Formation of c-Fos, STAT3, and Hepatocyte NF-1 Is Essential for Cytokine-Driven C-Reactive Protein Gene Expression
- (2014) T. Nishikawa et al. JOURNAL OF IMMUNOLOGY
- Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases
- (2014) Hiroshi Fujiwara et al. Modern Rheumatology
- Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens
- (2014) Atsushi Ogata et al. Modern Rheumatology
- Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions
- (2014) Norihiro Nishimoto et al. Modern Rheumatology
- Analysis of perioperative clinical features and complications after orthopaedic surgery in rheumatoid arthritis patients treated with tocilizumab in a real-world setting: results from the multicentre TOcilizumab in Perioperative Period (TOPP) study
- (2014) Shigeki Momohara et al. Modern Rheumatology
- IL-6 Stimulates Intestinal Epithelial Proliferation and Repair after Injury
- (2014) Kristine A. Kuhn et al. PLoS One
- Tocilizumab induces corticosteroid sparing in rheumatoid arthritis patients in clinical practice
- (2014) C. Fortunet et al. RHEUMATOLOGY
- Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
- (2014) Alejandro Souto et al. RHEUMATOLOGY
- Cardiovascular risk in rheumatoid arthritis: recent advances in the understanding of the pivotal role of inflammation, risk predictors and the impact of treatment
- (2014) E. Choy et al. RHEUMATOLOGY
- Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo
- (2014) Helen L. Wright et al. RHEUMATOLOGY
- The IL-6 feed-forward loop: A driver of tumorigenesis
- (2014) Qing Chang et al. SEMINARS IN IMMUNOLOGY
- Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
- (2014) Alan Kivitz et al. ARTHRITIS CARE & RESEARCH
- Effectiveness and Safety of Tocilizumab: Postmarketing Surveillance of 7901 Patients with Rheumatoid Arthritis in Japan
- (2013) T. Koike et al. JOURNAL OF RHEUMATOLOGY
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Retreatment efficacy and safety of tocilizumab in patients with rheumatoid arthritis in recurrence (RESTORE) study
- (2013) Norihiro Nishimoto et al. Modern Rheumatology
- Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study
- (2013) Norihiro Nishimoto et al. Modern Rheumatology
- Retention of tocilizumab and anti-tumour necrosis factor drugs in the treatment of rheumatoid arthritis
- (2013) Y Hishitani et al. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
- Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
- (2013) Atsushi Ogata et al. ARTHRITIS CARE & RESEARCH
- Role of interleukin-6 in stress, sleep, and fatigue
- (2012) Nicolas Rohleder et al. Annals of the New York Academy of Sciences
- Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
- (2012) Vivian P Bykerk et al. ANNALS OF THE RHEUMATIC DISEASES
- Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
- (2012) Maxime Dougados et al. ANNALS OF THE RHEUMATIC DISEASES
- The Effects of Interleukin-6 Signal Blockade on Fertility, Embryo-fetal Development, and Immunization In vivo
- (2012) Takayuki Sakurai et al. BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY
- p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation
- (2012) Ahmed Fahmi et al. CELLULAR SIGNALLING
- Atherogenic effects of TNF-α and IL-6 via up-regulation of scavenger receptors
- (2012) Misato Hashizume et al. CYTOKINE
- An Interleukin-6 Receptor-dependent Molecular Switch Mediates Signal Transduction of the IL-27 Cytokine Subunit p28 (IL-30) via a gp130 Protein Receptor Homodimer
- (2012) Christoph Garbers et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Interleukin-6 in pregnancy and gestational disorders
- (2012) Jelmer R. Prins et al. JOURNAL OF REPRODUCTIVE IMMUNOLOGY
- Pneumocystis jirovecii infection: an emerging threat to patients with rheumatoid arthritis
- (2012) S. Mori et al. RHEUMATOLOGY
- Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry
- (2011) H. C. Leffers et al. ANNALS OF THE RHEUMATIC DISEASES
- A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis
- (2011) E. Turkstra et al. CURRENT MEDICAL RESEARCH AND OPINION
- Sleep Disturbances and Interleukin 6 Receptor Inhibition in Rheumatoid Arthritis
- (2011) K. FRAGIADAKI et al. JOURNAL OF RHEUMATOLOGY
- Integrated safety in tocilizumab clinical trials
- (2011) Michael H Schiff et al. ARTHRITIS RESEARCH & THERAPY
- Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab
- (2010) A. Ogata et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu
- (2010) Joel M. Kremer et al. ARTHRITIS AND RHEUMATISM
- Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease
- (2010) S.-N. J. Song et al. BLOOD
- Differences in Wound Healing in Mice with Deficiency of IL-6 versus IL-6 Receptor
- (2010) M. M. McFarland-Mancini et al. JOURNAL OF IMMUNOLOGY
- Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials
- (2010) L. Campbell et al. RHEUMATOLOGY
- Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
- (2009) G. Jones et al. ANNALS OF THE RHEUMATIC DISEASES
- Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment
- (2009) S Nishida et al. ANNALS OF THE RHEUMATIC DISEASES
- The role of interleukins in insulin resistance and type 2 diabetes mellitus
- (2009) Bruno Fève et al. Nature Reviews Endocrinology
- IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
- (2008) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Laboratory and febrile features after joint surgery in patients with rheumatoid arthritis treated with tocilizumab
- (2008) M Hirao et al. ANNALS OF THE RHEUMATIC DISEASES
- Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study
- (2008) Mark C. Genovese et al. ARTHRITIS AND RHEUMATISM
- Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
- (2008) N. Nishimoto et al. BLOOD
- Interleukin-6 is an important in vivo inhibitor of intestinal epithelial cell death in mice
- (2008) X. Jin et al. GUT
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started